{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000167","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.889282+00:00","generated_at":"2026-06-06T14:48:39.323671+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD","bullets":["Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.","Primary objective: evaluate safety and tolerability; secondary: blood pressure reduction and pharmacokinetics.","IND review takes minimum 30 days; trial start subject to FDA effectiveness and funding.","This marks formal regulatory scrutiny toward pharmaceutical commercial registration for DehydraTECH technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000167","json":"https://secwatch.observer/filing/0001640334-24-000167.json","markdown":"https://secwatch.observer/filing/0001640334-24-000167.md","text":"https://secwatch.observer/filing/0001640334-24-000167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000167/0001640334-24-000167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000167/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:48:39.323671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}